Scarica l'app Stockscreener
396.93
0.08%
0.31
Pre-mercato:
396.00
-0.93
-0.23%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Risk adjusted return profile for Vertex Pharmaceuticals Incorporated analyzedJuly 2025 Sector Moves & Low Volatility Stock Recommendations - Newser
Stock Analysis | Vertex Pharmaceuticals OutlookMixed Signals and Key Fundamentals to Watch - AInvest
Is Vertex Pharmaceuticals Incorporated subject to activist investor interest2025 Pullback Review & Safe Entry Momentum Stock Tips - khodrobank.com
Automated trading signals detected on Vertex Pharmaceuticals IncorporatedEarnings Overview Summary & Short-Term Swing Trade Alerts - Newser
Why This Biotech Company Could Be a Growth Stock Powerhouse - AOL.com
Why This Biotech Company Could Be a Growth Stock Powerhouse - The Motley Fool
Why is Vertex Pharmaceuticals Incorporated stock going upTrend Reversal & Community Trade Idea Sharing Platform - khodrobank.com
Is Vertex Pharmaceuticals Incorporated part of any major indexTrade Exit Summary & Long-Term Capital Growth Ideas - khodrobank.com
Is Vertex Pharmaceuticals Incorporated stock reversal real or fake2025 Winners & Losers & Technical Pattern Based Buy Signals - Newser
Enlaza Therapeutics Forms $2.4 Billion Collaboration with Vertex Pharmaceuticals - PharmExec
Transcript : Vertex Pharmaceuticals Incorporated Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 11 - MarketScreener
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report? - sg.finance.yahoo.com
Enlaza takes the helm in a $2B+ Vertex deal - BioWorld MedTech
Why Vertex Pharmaceuticals (VRTX) Is on Loomis Sayles Growth Fund’s Detractors List - AInvest
Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List - Insider Monkey
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? - 富途牛牛
Top chart patterns to watch in Vertex Pharmaceuticals IncorporatedWeekly Trade Report & Fast Gaining Stock Reports - Newser
Is Vertex Pharmaceuticals Incorporated meeting your algorithmic filter criteriaMarket Volume Summary & Entry and Exit Point Strategies - Newser
Vertex teams with Enlaza to expand gene therapy options - The Pharma Letter
Should you wait for a breakout in Vertex Pharmaceuticals IncorporatedPortfolio Value Summary & High Accuracy Trade Signal Alerts - Newser
Tools to assess Vertex Pharmaceuticals Incorporated’s risk profileGap Up & Weekly Market Pulse Updates - Newser
Layoff Tracker: Novartis Continues Cutting Spree With 58 Sacked in New Jersey - BioSpace
Sentiment analysis tools applied to Vertex Pharmaceuticals Incorporated2025 Market WrapUp & Safe Entry Zone Tips - Newser
Does Vertex Pharmaceuticals Incorporated meet Warren Buffett’s criteriaQuarterly Trade Review & Growth-Oriented Investment Plans - khodrobank.com
Is Vertex Pharmaceuticals Incorporated attractive for institutional investorsJuly 2025 Technicals & Weekly Breakout Stock Alerts - khodrobank.com
What does recent volatility data suggest for Vertex Pharmaceuticals IncorporatedJuly 2025 Catalysts & Smart Swing Trading Alerts - Newser
Vertex Stock Surges 2.55% on 44% Volume Spike to $740M Ranking 135th as $2B Collaboration with Enlaza Drives Strategic Expansion - AInvest
Vertex locks on to $2B covalent biologics deal with Enlaza - FirstWord Pharma
Relative strength of Vertex Pharmaceuticals Incorporated in sector analysis2025 Investor Takeaways & Weekly Consistent Profit Watchlists - Newser
Does Vertex Pharmaceuticals Incorporated outperform in volatile markets2025 Fundamental Recap & Safe Entry Zone Tips - khodrobank.com
Enlaza Therapeutics strategic collaboration with Vertex Pharmaceuticals to develop War-Lock drug conjugates and T-cell engagers - MarketScreener
Vertex Pharmaceuticals Partners with Enlaza Therapeutics in $45 Million Deal to Develop Autoimmune and Gene-Editing Therapies - geneonline.com
Vertex enlists Enlaza for gene therapy conditioning and autoimmune disease pact - Endpoints News
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact - BioSpace
Vertex Pharma, Enlaza sign R&D pact worth $2B (VRTX:NASDAQ) - Seeking Alpha
Vertex forges $2B-plus alliance with Enlaza to create new autoimmune drugs, improve conditioning methods - Fierce Biotech
Vertex Pharmaceuticals Incorporated (VRTX) Slid on Softer Revenue and Earnings - Yahoo Finance
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases | VR - GuruFocus
Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases - Business Wire
Is Vertex Pharmaceuticals Incorporated still worth holding after the dipQuarterly Profit Review & Real-Time Buy Signal Alerts - Newser
Aug EndMonth: Does Vertex Pharmaceuticals Incorporated have declining or rising EPS2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - khodrobank.com
Bank Watch: Is Vertex Pharmaceuticals Incorporated currently under institutional pressureJuly 2025 Sector Moves & Free AI Powered Buy and Sell Recommendations - khodrobank.com
Vertex Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Vertex Pharmaceuticals Incorporated stock retracement – recovery analysis2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
Using Bollinger Bands to evaluate Vertex Pharmaceuticals IncorporatedWeekly Stock Analysis & Free Fast Gain Swing Trade Alerts - Newser
Vertex price shows more negative signsForecast today01-09-2025 - Economies.com
Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Yahoo Finance
Vertex Pharmaceuticals Incorporated stock trendline breakdownAnalyst Downgrade & Entry Point Confirmation Signals - Newser
Tools to monitor Vertex Pharmaceuticals Incorporated recovery probabilityTrade Analysis Summary & Capital Efficiency Focused Strategies - Newser
Price momentum metrics for Vertex Pharmaceuticals Incorporated explainedWeekly Trade Report & AI Forecasted Entry and Exit Points - Newser
Vertex Pharmaceuticals Incorporated Builds Base for Possible Rebound getLinesFromResByArray error: size == 0 - thegnnews.com
Visualizing Vertex Pharmaceuticals Incorporated stock with heatmapsJuly 2025 Sentiment & Free Reliable Trade Execution Plans - Newser
Will earnings trigger a reversal in Vertex Pharmaceuticals IncorporatedPortfolio Performance Summary & Technical Confirmation Trade Alerts - Newser
What high frequency data says about Vertex Pharmaceuticals IncorporatedRate Cut & Daily Risk Controlled Trade Plans - Newser
When is the best time to exit Vertex Pharmaceuticals IncorporatedTrade Exit Summary & Technical Confirmation Trade Alerts - Newser
1.37%
5.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):